For example, a higher prevalence of epidermal growth factor receptor (EGFR) mutation among female non-small-cell lung cancer (NSCLC) patients of East Asian descent who are non-smokers often results in dramatic responses to EGFR tyrosine kinase inhibitors, leading to a more favorable prognosis for overall survival [9,11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.